How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline

For CGT developers actively advancing therapies, manufacturing strategy is no longer theoretical; it’s a series of high-stakes decisions that directly impact timelines, cost, scalability, and patient access. Should you centralize, decentralize, or build something in between? And more importantly, how do you know when your model is working, or when it’s starting to break? 

Join us for this timely Cell & Gene Live, moderated by Cell & Gene's Chief Editor, Erin Harris, featuring expert panelists, Omkar Kawalekar, Manufacturing & Supply Chain Lead, NextGen Therapies at Deloitte Consulting and Zoe Zheng, Executive Director Pipeline Technical and Strategic Lead at Legend Biotech. They will walk through practical decision frameworks, real operating models, and the hidden tradeoffs behind each approach so you can make smarter, pipeline-aligned manufacturing decisions.